Wiley Welcomes Dr. Karen N. Madden to Board of Directors

In a significant move aimed at bolstering its leadership in research and education, Wiley (NYSE: WLY), a global frontrunner in publishing and a trusted partner in learning, has announced the appointment of Dr. Karen N. Madden to its Board of Directors. This announcement, made on March 5, 2025, underscores Wiley's commitment to harnessing innovative strategies in the ever-evolving landscape of knowledge dissemination.

Dr. Madden currently serves as the Senior Vice President and Chief Technology Officer at MilliporeSigma, the U.S. and Canada Life Science division of Merck KGaA, Darmstadt, Germany. In her role, she is instrumental in shaping the Technology Roadmap and long-term R&D strategy, focusing on breakthrough innovations that can significantly impact the life sciences sector. Her leadership extends to the Life Science Innovation Board, where she balances the pursuit of high-impact long-term programs with critical short-term growth projects.

Before her tenure at MilliporeSigma, Dr. Madden held the position of Senior Vice President and Chief Innovation Officer at PerkinElmer, driving innovation across various business sectors. Her rich experience in research and development positions her as a valuable asset to Wiley's strategic vision.

Matthew Kissner, President & CEO of Wiley, expressed enthusiasm about Dr. Madden's appointment, highlighting her extensive experience in science, technology, and innovation. He emphasized that her strategic insights and expertise will be invaluable as Wiley continues its transformation to deliver trusted content and services that foster progress.

Dr. Madden's proactive engagement with the global scientific community, including partnerships with key universities and industry organizations, aligns perfectly with Wiley's mission of advancing knowledge. Her role as U.S. Country Speaker for Merck KGaA further exemplifies her commitment to driving collaboration within the research community.

In her remarks about joining Wiley's Board, Dr. Madden noted her honor in contributing to an organization that has played a pivotal role in shaping global knowledge for 218 years. She expressed a deep resonance with Wiley's commitment to leveraging authoritative content and data for societal benefit.

Jesse Wiley, Board Chair, echoed this sentiment, stating, "Karen brings a wealth of knowledge in R&D and innovation that will be tremendously valuable to Wiley." He underscored her connections within the global research community as a vital aspect of Wiley’s ongoing commitment to advancing knowledge.

Dr. Madden's academic credentials are equally impressive. She earned her Ph.D. in chemistry with a specialization in molecular biology, biochemistry, and biophysics from Rutgers University. Additionally, she holds a Master of Science in chemistry from the University of Pennsylvania and a Bachelor of Arts in chemistry from Boston University. Her involvement with several prestigious organizations, including the Analytical, Life Science, and Diagnostics Association, demonstrates her dedication to the field.

Wiley's decision to appoint Dr. Madden to its Board of Directors reflects its strategic emphasis on innovation and excellence in research and learning. As the company continues to navigate the complexities of the information landscape, the insights and expertise brought by Dr. Madden will undoubtedly play a crucial role in shaping its future direction. With a commitment to unlocking human potential, Wiley is poised to continue delivering valuable content and services that drive progress for researchers, students, and professionals alike.